David Feldman PhD

David Feldman received his PhD in Biology at the State University of New York at Binghamton. After completing a Post-doctoral Research Fellowship at the Cleveland Clinic Foundation, he joined the pharmaceutical sector to begin a career in pre-clinical research in cardiovascular and kidney disease that spanned over 30 years at Hoffmann-La Roche Inc., Ciba Geigy Corp., and Novartis Pharmaceuticals. He was the research representative on the team at Novartis that brought to the market the first renin inhibitor, a new class of medicine for high blood pressure.

Dr Feldman joined the National Kidney Foundation in 2015 to follow his passion for impacting, through education, the lives of patients living with kidney disease. He is currently a Medical Project Director at the NKF, where initially, he worked on overcoming barriers to the low rate of diagnosis of chronic kidney disease in the US. He now focuses on Externally-Led Patient Focused Drug Development meetings. Dr Feldman recently organized the first kidney-related EL-PFDD meeting- for complement 3 glomerulopathy (C3G), a rare and devastating kidney disease. Dr Feldman’s knowledge of kidney disease and his strong commitment to helping kidney patients permit him to interact with patients and other stakeholders on both a scientific & compassionate level.